The GLP-1 Disclosure Gap: Designing Fair Reinsurance Evidence for a Fast-Changing Drug Market

The GLP-1 disclosure gap is the evidence problem life reinsurers cannot ignore. Applicants are taking these drugs at scale, but disclosure rates on insurance applications lag far behind prescription volumes. The reinsurance question is not whether GLP-1 use matters for mortality, it is whether the application process actually captures it, and how to design evidence questions that close the gap fairly for both insurers and applicants.

Why has the GLP-1 disclosure gap become a first-order reinsurance evidence problem?

The GLP-1 disclosure gap has become a first-order problem because millions of people now obtain GLP-1 drugs through channels that do not look like traditional medical treatment, and application forms designed for a pre-GLP-1 world do not prompt disclosure. The result is a portfolio where a significant share of metabolic risk sits invisible in the underwriting data.

The gap is structural, not accidental. GLP-1 drugs are prescribed through telehealth platforms, med-spas, and direct-to-consumer websites. An applicant who obtains semaglutide through an online provider for "weight wellness" may never think of it as a medical treatment that belongs on an insurance application. The individual life reinsurance mortality data pipeline depends on underwriting capturing the right information at the point of application, and when the form fails to surface GLP-1 use, every downstream assumption, pricing, mortality, reserving, is built on an incomplete picture.

For ceded reinsurance teams, the disclosure gap creates two distinct risks. The first is that GLP-1 users who would have been rated or declined enter the portfolio at standard terms because their medication history was never captured. The second is that the cedent cannot quantify how large the gap is, so the reinsurer cannot price it even if both parties want to. Pricing unknown risk in reinsurance is always challenging, but when the risk is known to exist and simply unmeasured, the pricing penalty is heavier than when the risk itself is genuinely new. Cedents who can measure the disclosure gap earn a quantifiable adjustment; those who cannot are loaded for the worst case.

What goes wrong when GLP-1 disclosure is incomplete?

Incomplete GLP-1 disclosure fails in five ways: standard-rate underwriting for treated metabolic risk, pooled mortality experience that masks the non-disclosed cohort, application questions that do not trigger disclosure, evidence sources that are not triangulated, and the absence of a materiality framework that distinguishes genuine non-disclosure from ambiguous cases.

Each failure mode compounds in a portfolio that is accumulating GLP-1 exposure faster than its evidence processes can see it.

1. How do non-disclosed GLP-1 lives enter at standard rates?

Non-disclosed GLP-1 lives enter at standard rates because the underwriting workflow never triggers a rating action. The applicant reports height and weight, and if GLP-1 has reduced weight below rating thresholds, the build alone may not flag. The lab results may show controlled HbA1c, and without the medication context, the underwriter sees a healthy life.

This is the quietest form of anti-selection. A life that required pharmacotherapy to reach its current metabolic profile is not the same as a life that never needed it, but the underwriting file treats them identically. Over time, standard-rate blocks accumulate GLP-1-treated lives at terms that do not reflect the underlying risk, and mortality experience drifts against the assumptions. AI in reinsurance underwriting applications are beginning to detect these patterns, but most legacy underwriting workflows are blind to them.

2. Why does pooled mortality experience mask the disclosure problem?

Pooled mortality experience masks the disclosure problem because deaths among non-disclosed GLP-1 users look like deaths among untreated standard lives. The portfolio's overall mortality drifts upward, but the cause, undisclosed pharmacotherapy, never appears in the analysis because the medication was never recorded.

A mortality study that stratifies by disclosed conditions will miss this cohort entirely. The deterioration gets attributed to population-level trends, aging, or random volatility, when in fact it is a systematic data-quality failure. A treaty data quality checker configured to flag portfolios with high GLP-1 prescribing in their geography but low GLP-1 disclosure in their applications would surface the discrepancy before it becomes a claims problem.

3. How do legacy application questions fail to capture GLP-1 use?

Legacy application questions fail to capture GLP-1 use because they ask about "prescription medications," which many GLP-1 users interpret as drugs for illness, not wellness. They do not list semaglutide, tirzepatide, or brand names as examples, and they assume the applicant knows their medication is clinically relevant.

The behavioral design of the question matters more than its legal scope. An applicant completing a form online at 11 p.m. will skim past "are you taking any prescription medications" but may pause at "are you taking any weight-management or diabetes medications such as Ozempic, Wegovy, Mounjaro, or similar drugs?" The second question triggers recognition where the first triggers an automatic "no." AI in critical illness insurance is teaching the industry that question design changes disclosure rates, and life underwriting is learning the same lesson.

4. Why is a single evidence source insufficient to close the gap?

A single evidence source is insufficient because no one database captures the full GLP-1 picture. Pharmacy benefit records may miss cash-pay prescriptions. Medical claims may not capture telehealth encounters. Applicant disclosure alone is unreliable. Only triangulation across sources produces a defensible picture.

A cedent that relies solely on applicant disclosure may miss the majority of GLP-1 use. One that relies solely on a pharmacy database may miss cash-pay and compounding-pharmacy prescriptions. The facultative risk assessment process for large individual cases illustrates the principle: the more sources you check, the fewer gaps survive, but each source adds cost and friction, so the design question is which combination is cost-effective and fair.

5. What happens when there is no materiality framework for disclosure disputes?

Without a materiality framework, every non-disclosure looks like misrepresentation and every disclosure gap becomes a potential claims dispute. A GLP-1 prescribed for borderline prediabetes is not the same as one prescribed for morbid obesity with heart failure, but without a framework, both look like "undisclosed medication."

The reinsurance claims process needs a graduated approach. A missed disclosure of a six-month GLP-1 course for fifteen pounds of weight loss is not material in the same way as undisclosed semaglutide for uncontrolled diabetes. The reinsurance claims tracking function benefits from clear materiality thresholds that separate genuine underwriting failures from technical non-disclosure that did not change the risk assessment.

Design fairer, more effective GLP-1 evidence collection for your life underwriting workflow

Talk to Our Specialists

Visit Insurnest to learn how we help life carriers and reinsurers build disclosure-question design, evidence triangulation, and materiality frameworks for the GLP-1 era.

What do ceded re managers at life carriers actually expect from a redesigned disclosure process?

Ceded re managers expect a disclosure process that captures GLP-1 use without lengthening the application, uses plain-language question design informed by behavioral evidence, triangulates pharmacy claims and lab data where cost-effective, includes a materiality framework for disclosure disputes, and produces auditable disclosure-completeness metrics the reinsurer can review at renewal.

It is six weeks before the mid-year treaty review. Sarah Kemper, the ceded re manager at a large US life carrier, is preparing the exposure submission for her reinsurance panel. The lead reinsurer's underwriter sent a note after last year's renewal: the carrier's GLP-1 disclosure rate, at 1.2% of applications, was well below the regional prescribing rate of 7%. The reinsurer asked whether the gap was a disclosure problem, a selection problem, or both. Sarah had no answer she could defend with data.

This year Sarah wants to present a redesigned process. The carrier has piloted plain-language GLP-1 questions in a subset of distribution channels and seen disclosure rates triple. It has begun matching pharmacy records to a sample of policies and quantifying the residual gap. And it has built a materiality framework that distinguishes non-disclosure requiring rating action from non-disclosure that would not have changed the underwriting decision.

That framework is what Sarah wants to show the panel. Not that every GLP-1 user is now perfectly disclosed, because they are not, but that the carrier knows the size of the gap, is shrinking it, and can quantify what remains. That is a far stronger position than last year's silence, and it changes the renewal conversation from defensive to constructive.

Beneath that shift sit the concrete asks that ceded re managers hear from their reinsurance partners.

Plain-language questions with brand-name examples. "Stop asking 'prescription medications' and start asking 'diabetes or weight-management medications such as Ozempic, Wegovy, or Mounjaro.'" Recognition prompts work better than generic prompts.
Dynamic questioning triggered by build, labs, or weight change. "If the applicant's BMI crossed a threshold in the last two years, ask specifically about weight-management treatments." Static forms miss the lives most likely to have used GLP-1.
Pharmacy-record matching where legally permitted and cost-justified. "Run a pharmacy check on a sample of policies and compare to disclosure rates." Even a partial match reveals the gap's magnitude and direction.
A materiality framework that tiers non-disclosure by clinical severity. "Show me a policy for when undisclosed GLP-1 triggers rescission, rating adjustment, or acceptance." Blanket approaches to non-disclosure create legal risk and reputational friction.
Disclosure-completeness metrics in the renewal submission. "Report disclosure rates against external prescribing benchmarks by region, age band, and product." A metric is the first step toward managing the gap rather than just living with it.
Evidence-collection workflow that does not add minutes to the application. "Keep the disclosure process fast, because the alternative is non-disclosure plus a longer form, which is worse than either alone." Behavioral speed matters for completion rates.
Broker and agent training on why GLP-1 disclosure matters. "The agent who says 'you don't need to mention that, it's just for weight' is creating a claims dispute five years from now." Frontline training reduces the gap at its source.
Auditability of disclosure rates by channel and product. "If one distribution channel has a 0.5% disclosure rate and another has 4%, I need to know why." Channel-level variation is a diagnostic, not a noise term.
A documented process for handling GLP-1 disclosure at claims time. "When a death claim lands and the pharmacy history shows GLP-1 that was never disclosed, what happens?" The claims protocol must be defined before the claim arrives.
Willingness to share the disclosure-improvement roadmap with reinsurers. "Show me the plan, not just the number." A carrier actively closing the gap earns more patience than one that reports the same low disclosure rate year after year.

The real ask is not zero non-disclosure; that is unrealistic. It is a measured, managed, shrinking gap, disclosed transparently, with a fair framework for the cases that still slip through.

How can life carriers close the GLP-1 disclosure gap in underwriting?

Life carriers can close the GLP-1 disclosure gap by redesigning application questions with behavioral principles, adding dynamic branching rules, integrating pharmacy-record checks into evidence collection, training distribution partners on disclosure importance, building post-issue audit processes, and producing disclosure-completeness reporting that satisfies reinsurance due diligence.

This is where evidence design meets technology. Each capability below addresses one dimension of the gap and together they form a defensible disclosure framework.

1. How does behavioral question design increase GLP-1 disclosure rates?

Behavioral question design increases disclosure rates by replacing generic clinical language with specific, recognizable examples, using active framing that normalizes disclosure, and positioning the question where the applicant is already thinking about weight or health history rather than as an isolated item.

An application that asks "in the last five years, have you taken any weight-management or diabetes medications, including Ozempic, Wegovy, Mounjaro, or similar drugs?" will capture more GLP-1 use than one that asks "list all prescription medications taken in the last five years." The specificity triggers recognition, and the framing signals that GLP-1 use is expected and normal, not something to hide. AI in underwriting tools can test question variants and measure which ones produce disclosure rates closest to external prescribing benchmarks.

2. What role do dynamic branching rules play in capturing GLP-1 disclosure?

Dynamic branching rules trigger GLP-1-specific questions when the applicant's build, reported weight change, or lab results suggest possible use, rather than asking every applicant a question most will answer "no." The question fires only for the subset of applicants where it is relevant.

A thirty-year-old applicant with stable BMI of 22 does not need a GLP-1 question. A forty-five-year-old applicant whose BMI dropped from 34 to 27 in eighteen months should be asked specifically about how that weight loss was achieved, including GLP-1 use. Branching rules make the disclosure process more efficient and more targeted, and they can be built into automated underwriting workflows without lengthening the form for most applicants.

3. How does pharmacy-record integration complement applicant disclosure?

Pharmacy-record integration complements applicant disclosure by providing an independent check on what medications the applicant has filled, regardless of what they report. The comparison between disclosed and filled medications is the disclosure-gap metric itself.

The integration must be designed carefully. Not all pharmacy databases cover all prescriptions; cash-pay, compounding, and some telehealth channels may not appear. The match rate must be disclosed alongside the gap so reinsurers understand the limitations. But even an imperfect match provides a floor: if the pharmacy database shows GLP-1 fills for 5% of the portfolio and only 1.5% disclosed, the direction and approximate magnitude of the gap are clear, and that is actionable information for treaty pricing.

4. Why does distribution-partner training matter for disclosure completeness?

Distribution-partner training matters because the agent or broker is often the applicant's first filter. An agent who tells a prospect "you don't need to mention that weight-loss shot" is creating a non-disclosure that will surface at claim time, and the carrier bears the liability.

Training programs that explain the reinsurance implications, the claims consequences of non-disclosure, and the carrier's fair-treatment framework give agents the confidence to have the disclosure conversation rather than avoiding it. AI in group health insurance for reinsurers has shown that agent behavior is a measurable input into portfolio quality, and disclosure training is one of the highest-return interventions a carrier can make.

5. How do post-issue audit processes close the gap retrospectively?

Post-issue audit processes close the gap retrospectively by sampling issued policies, running pharmacy checks where legally permitted, and comparing disclosed to filled GLP-1 use. The audit quantifies the existing gap in the in-force block and identifies patterns that the underwriting process can fix prospectively.

A carrier that discovers its in-force book contains a 4% undisclosed GLP-1 rate can adjust pricing assumptions for that block, redesign questions for new business, and disclose the finding to reinsurers proactively rather than waiting for a claim to surface it. The loss reserve development implications of undiagnosed anti-selection are real, and post-issue audits are the tool that diagnoses it.

6. What does disclosure-completeness reporting for reinsurers look like?

Disclosure-completeness reporting for reinsurers is a structured section of the renewal submission that shows disclosed GLP-1 rates against external prescribing benchmarks, by product, channel, age band, and region, with a narrative on methodology, limitations, and the carrier's improvement plan.

This reporting converts the disclosure gap from an awkward conversation into a monitored KPI. When the reinsurer sees that disclosure rates rose from 1.2% to 2.8% year-over-year and that the carrier's pharmacy-match pilot estimates a residual gap of 2%, the conversation becomes "how do we close the remaining 2%," not "do you even know what is in your book." Reinsurance audit preparation technology can produce this reporting as a recurring output, making it a routine rather than a project.

Close the disclosure gap with Insurnest's underwriting evidence technology for life reinsurance

Talk to Our Specialists

Visit Insurnest to see how we help carriers redesign GLP-1 disclosure questions, integrate pharmacy checks, and produce disclosure-completeness reporting that reinsurers trust.

What does a well-designed GLP-1 disclosure framework look like?

A well-designed GLP-1 disclosure framework combines plain-language questioning, dynamic branching, pharmacy-record checks on a sample basis, agent training, post-issue audits, and a materiality policy for non-disclosure that is fair, consistent, and defensible to both reinsurers and regulators.

Return to Sarah and her renewal submission. This year, the disclosure-completeness section shows that the carrier's GLP-1 disclosure rate has risen from 1.2% to 2.8% after the question redesign, with the new plain-language format achieving 3.5% in pilot channels. The pharmacy-match audit, run on a representative sample, finds a residual gap of approximately 2%, meaning the carrier has closed about half the estimated total gap and can show the reinsurer exactly what remains.

The materiality framework is in the appendix: GLP-1 use for diabetes with complications is treated as material non-disclosure; use for weight management without comorbidities is assessed case by case; and use that would not have changed the rating decision is documented but not pursued. The reinsurance panel can see the logic and challenge the thresholds if they disagree, but they cannot say the carrier is hiding the problem.

That submission changes the conversation. The lead reinsurer's underwriter, who last year flagged the disclosure gap as a concern, now spends the meeting discussing cohort-level mortality assumptions for the disclosed GLP-1 population and whether the residual undisclosed population warrants a small uncertainty load. The discussion is quantitative, not defensive, and the terms reflect the measured gap rather than the feared one. In a market where transparency earns capacity, that is the difference between a tense renewal and a collaborative one.

Build a defensible GLP-1 disclosure framework with Insurnest's evidence-design technology

Talk to Our Specialists

Visit Insurnest to learn how we help carriers and reinsurers design fair, effective GLP-1 disclosure processes that close the evidence gap.

Conclusion

For life carriers and their reinsurance partners, the GLP-1 disclosure gap is not a data-quality inconvenience; it is a structural underwriting failure that misprices metabolic risk across the portfolio. The gap exists because application forms have not kept pace with how these drugs are prescribed and perceived, and closing it requires redesigning evidence collection from first principles.

For ceded reinsurance teams, the message is clear. A carrier that cannot measure its disclosure gap is priced as if the gap is large, undisclosed, and unresolvable. A carrier that can measure it, shrink it, and report it transparently earns differentiated terms because the reinsurer can price the known residual rather than loading for the unknown.

The GLP-1 disclosure gap will not close by itself. It closes when carriers redesign questions with behavioral insight, add dynamic branching, integrate pharmacy data, train their distributors, audit their in-force blocks, and build the reporting that turns an invisible problem into a managed metric. The treaties that take this seriously will be the ones that survive the next decade of metabolic pharmacotherapy without surprises.

Frequently asked questions

What is the GLP-1 disclosure gap in life insurance underwriting?

The GLP-1 disclosure gap is the difference between what applicants actually take and what they disclose on insurance applications. Many GLP-1 users do not consider weight-loss medication a reportable medical treatment, creating systematic underreporting.

Why do applicants underreport GLP-1 use on insurance applications?

Applicants often view GLP-1s as wellness or cosmetic treatments, not medical therapy. Direct-to-consumer prescribing channels, telehealth prescriptions, and non-diabetes indications blur the line between lifestyle choice and reportable medical history.

How should reinsurers design fair GLP-1 disclosure questions?

Disclosure questions should use plain-language drug names, list common brand examples, specify both diabetes and weight-management contexts, and avoid clinical jargon. Behavioral design matters as much as the legal wording of the question.

What evidence sources can verify GLP-1 use when disclosure is incomplete?

Pharmacy benefit records, prescribing databases, medical claims with diagnosis codes, and lab results showing HbA1c trends can triangulate GLP-1 use. No single source is perfect, but multiple data points together build a reliable picture.

Does GLP-1 non-disclosure constitute material misrepresentation for reinsurance?

It can, depending on the jurisdiction and materiality of the undisclosed condition. A GLP-1 prescribed for obesity with comorbidities is materially different from one for borderline weight management, and reinsurers need to distinguish them.

How does GLP-1 disclosure behavior vary by distribution channel?

Direct-to-consumer and telehealth channels produce lower disclosure rates than traditional physician-prescribed channels because the applicant may never have discussed the medication in a clinical setting they consider relevant to insurance underwriting.

What role do medical information bureaus play in closing the GLP-1 disclosure gap?

Pharmacy-history databases and prescription monitoring programs can supplement applicant disclosure, but they vary by jurisdiction and often exclude weight-management-only prescriptions. Reinsurers should understand these limitations before relying on database checks alone.

How can cedents improve GLP-1 disclosure rates without lengthening application forms?

Cedents can use dynamic questioning that branches when weight change or metabolic markers are flagged, add plain-language GLP-1 examples to existing medication questions, and train underwriters to probe disclosure at the point of evidence collection.

About the author

Hitul Mistry is the Founder of Insurnest, an InsurTech company that engineers end-to-end technology exclusively for the insurance industry serving carriers, TPAs, MGAs, brokers, and reinsurers across India, the UAE, and the US. With more than a decade of insurance domain experience, he has built systems spanning underwriting automation, AI-powered underwriting intelligence, claims management, rating and quoting, broking and agency platforms, and reinsurance automation across Health/GMC, Group Life, Motor, P&C, and Reinsurance. Insurnest doesn't adapt generic software to insurance; it builds from the workflow up.

Connect with Hitul on LinkedIn.

Posts tagged with#GLP-1 disclosure

The GLP-1 Disclosure Gap: Designing Fair Reinsurance Evidence for a Fast-Changing Drug Market